Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dengue tetravalent vaccine, live, attenuated
- Development stage
- Approved
- Lead developer
- Takeda
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**Dengue tetravalent vaccine, live, attenuated** is a recombinant, live-attenuated, tetravalent chimeric dengue vaccine marketed as **Dengvaxia**. It contains four yellow fever 17D-backbone chimeric viruses that express the pre-membrane and envelope proteins of dengue virus serotypes 1 through 4, eliciting active immune responses including neutralizing antibodies against all four dengue serotypes. Developed by Sanofi, it is used to prevent dengue caused by DENV-1, DENV-2, DENV-3, and DENV-4. Its use is restricted to people with documented prior dengue infection because vaccination of dengue-naive individuals can increase the risk of severe or hospitalized dengue after subsequent infection. In the United States, it is approved for people aged 6 through 16 years with laboratory-confirmed prior dengue infection who live in dengue-endemic areas. ([fda.gov](https://www.fda.gov/media/124379/download))
- Brand names
- Dengvaxia
- Other names
- CYD dengue vaccineDengue tetravalent vaccine, liveDengue tetravalent vaccine, live, attenuated
02
Targets
Dengue virus envelope protein
Beyond the preview
Go deeper on dengue tetravalent vaccine, live, attenuated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dengue tetravalent vaccine, live, attenuated.